Autolus Therapeutics (NASDAQ:AUTL) Trading 10.8% Higher

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price was up 10.8% during trading on Monday . The stock traded as high as $6.97 and last traded at $6.97. Approximately 16,386 shares changed hands during trading, a decline of 99% from the average daily volume of 1,199,597 shares. The stock had previously closed at $6.29.

A number of equities research analysts have recently issued reports on AUTL shares. Zacks Investment Research raised shares of Autolus Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Monday, August 2nd. Mizuho restated a “buy” rating and issued a $18.00 target price on shares of Autolus Therapeutics in a research report on Monday, August 2nd. Finally, Jefferies Financial Group raised shares of Autolus Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $6.00 to $12.00 in a research note on Monday, June 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $13.43.

The stock’s fifty day moving average is $6.27 and its 200 day moving average is $6.27. The company has a market capitalization of $501.93 million, a P/E ratio of -2.66 and a beta of 1.72.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.03. The company had revenue of $1.65 million for the quarter, compared to the consensus estimate of $0.31 million. Autolus Therapeutics had a negative net margin of 4,890.43% and a negative return on equity of 56.93%. On average, equities research analysts predict that Autolus Therapeutics plc will post -2 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC raised its holdings in Autolus Therapeutics by 162.7% in the second quarter. Lindbrook Capital LLC now owns 7,882 shares of the company’s stock worth $52,000 after purchasing an additional 4,882 shares in the last quarter. HRT Financial LP purchased a new stake in Autolus Therapeutics in the first quarter valued at approximately $62,000. Tudor Investment Corp Et Al purchased a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $93,000. Deutsche Bank AG acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth approximately $99,000. Finally, XTX Topco Ltd acquired a new stake in shares of Autolus Therapeutics in the 2nd quarter worth $101,000. Hedge funds and other institutional investors own 33.54% of the company’s stock.

Autolus Therapeutics Company Profile (NASDAQ:AUTL)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.

Featured Story: How do investors use RSI to grade stocks?

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.